We turn natural bacterial components into antimicrobial weapons
What is ENZYBIOTX?
Enzybiotx is a biotech company which engages in the discovery, development and commercialization of enzybiotics – enzyme based non-antibiotic therapeutics. We design, develop and adjust enzybiotics to your needs.
About
Post-antibiotic era is around the corner and if we do not stop it, soon we will be facing increased death rates caused by ordinary bacterial infections and standard medical procedures will be too risky, as in the 19th Century. Our expertise in protein engineering helps us to develop and deliver much needed solutions.
Safe & effective
Completely novel approach – a new generation non-antibiotic antimicrobials, which are safe, effective and selectively eliminate antibiotic resistant strains and biofilms.
Over 10 years of experience
Our discovery platform is based on over a decade of research of bacterial proteins which we turn into antimicrobial weapons.
Individual approach
Once an enzybiotic is discovered, we can adjust its efficacy, specificity and stability to the potential applications. The best candidates can be offered to our clients for further co-development into antimicrobial component of client’s final products.
Projects
EIT Food – Test Farms
Funding provided: 3 000 EUR
Source of funding: EIT Food
Date of implementation: 08.2021 – 12.2022
Aim of the project: Testing in real life conditions of our enzymes as antistaphylococcal product for disinfecting surfaces in animal husbandry facilities, e.g. cowshed, piggery.
Women TechEU
Funding provided: 75 000 EUR
Source of funding: Horizon Europe
Date of implementation: 06.2022 – 01.2023
Title of the project: UPGRADING BUSINESS POTENTIAL OF ENZYBIOTX
Aims of the project:
- Support the development of the company as an organization,
- Support in product and market validation,
- Support in development of women co-founders through coaching and mentoring and expanding their professional network, leading ultimately to the growth of Enzybiotx in a sustainable manner.
Fortissimo Plus EuroHPC JU
Funding provided: 150 000 EUR
Source of funding: EuroHPC JU FFPplus Fortissimo Plus
Date of implementation: 01.05.2026 – 31.07.2027
Title of the project: Predicting and ranking peptide-enzybiotic conjugates with enhanced intracellular bacteriolytic activity
Aims of the project:
The project aims to develop innovative antimicrobial agents (enzybiotics) capable of penetrating eukaryotic cell membranes and eliminating hidden intracellular reservoirs of Staphylococcus bacteria. While the current formulation effectively destroys bacteria outside host cells, pathogens that reside within cells remain inaccessible, contributing to persistent and chronic infections. To overcome this challenge, researchers are leveraging EuroHPC supercomputing infrastructure and state-of-the-art computational enzymology to design an optimised cell-penetrating conjugate. This engineered formulation is intended to enable efficient intracellular delivery while preserving the full bacteriolytic activity of the antimicrobial agent. By targeting both extracellular and intracellular bacterial populations, the project aims to provide a more effective treatment strategy for difficult-to-treat infections. Ultimately, the development of such highly targeted antimicrobials represents a promising advance in addressing the growing global challenge of antibiotic resistance.
Mikrogranty
Funding provided: 120 000 PLN (160 000 PLN overall budget)
Source of funding: Projekt „μGranty B+R dla przedsiębiorstw”” w ramach Regionalnego Programu Operacyjnego Województwa Pomorskiego na lata 2014-2020, Osi Priorytetowej 01. Komercjalizacja wiedzy, Działania 01.01. Ekspansja przez innowacje, Poddziałania 01.01.01. Ekspansja przez innowacje – wsparcie dotacyjne
Date of implementation: 01.01.2023 – 30.06.2023
Aims of the project: Development of a cosmetic prototype for Atopic Dermatitis supporting natural skin microbial balance.
